

# SENATE BILL 495

J1

6lr1038

---

By: **Senators Nathan–Pulliam, Benson, Currie, Ferguson, Guzzone, Kelley, Klausmeier, Lee, McFadden, Muse, Raskin, and Young**

Introduced and read first time: February 3, 2016

Assigned to: Education, Health, and Environmental Affairs

---

## A BILL ENTITLED

1 AN ACT concerning

2 **Statewide Steering Committee on Services for Adults With Sickle Cell**  
3 **Disease – Infusion Center – Study**

4 FOR the purpose of requiring the Statewide Steering Committee on Services for Adults  
5 with Sickle Cell Disease to study adult sickle cell disease infusion center models,  
6 complete a certain cost–benefit analysis, and make certain recommendations  
7 regarding the establishment of an adult sickle cell disease infusion center; requiring  
8 that a certain cost–benefit analysis include a certain determination regarding cost  
9 savings; requiring the Committee to submit an interim and a final report to the  
10 Governor, the Office of Minority Health and Health Disparities, and certain  
11 committees of the General Assembly on or before certain dates; and generally  
12 relating to a study regarding the establishment of an adult sickle cell disease  
13 infusion center.

14 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
15 That:

16 (a) The Statewide Steering Committee on Services for Adults with Sickle Cell  
17 Disease shall:

18 (1) study adult sickle cell disease infusion center models;

19 (2) complete a cost–benefit analysis regarding the feasibility of  
20 establishing an adult sickle cell disease infusion center that offers genetic counseling and  
21 performs outreach regarding sickle cell anemia for adults; and

22 (3) make recommendations based on the findings, including, if it is  
23 determined that an adult sickle cell disease infusion center should be established, where  
24 the infusion center should be located.

---

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 (b) The cost–benefit analysis conducted under subsection (a)(2) of this section  
2 shall include a determination of whether savings, both overall and to the State, would  
3 result from the establishment of a sickle cell disease infusion center.

4 (c) (1) On or before December 1, 2016, the Committee shall submit an interim  
5 report of its final findings and recommendations to the Governor, the Office of Minority  
6 Health and Health Disparities, and, in accordance with § 2–1246 of the State Government  
7 Article, the Senate Education, Health, and Environmental Affairs Committee and the  
8 House Health and Government Operations Committee.

9 (2) On or before December 1, 2017, the Committee shall submit a final  
10 report of its findings and recommendations to the Governor, the Office of Minority Health  
11 and Health Disparities, and, in accordance with § 2–1246 of the State Government Article,  
12 the Senate Education, Health, and Environmental Affairs Committee and the House  
13 Health and Government Operations Committee.

14 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June  
15 1, 2016.